Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>®</sup>Therapeutic Vaccine

• 作者: Raiza Ruiz-Lorente Sayly Alfonso Eduardo Santiesteban Yamilka Sánchez Kirenia Camacho Erasmo Mendoza Carmen Elena Viada Ramón Ortiz Ihosvannys Carreño Mayelin Troche Meylan Cepeda Ana Rosa Vals Leticia Cabrera Annia Gorte Delmis Batista Milagros Domenech Yanela Santiesteban Yuliannis Santiesteban Daymys Estevez Jessica García-Viamontes Conrado Ramos Mico Mayra Ramos-Suzarte
• 来源期刊: 癌症治疗(英文)
• 学科: 医学
• 关键词: CIMAvax-EGF® NIMOTUZUMAB Survival Safety Advanced Cervical Cancer
• 年，卷（期）: azzlyw_2021,（3）
• 页码范围: 146-156
• 页数: 11页
• 分类号: R73

摘要

Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence,<span><span><span style="color:black;"> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;">^&reg;</span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, the humanized mAb nimotuzumab </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with </span><span style="font-family:Verdana;">a more</span><span style="font-family:Verdana;"> than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">;1.1</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months fo